L-siRNA |
|
Vaxjo ID |
401 |
|
Vaccine Adjuvant Name |
L-siRNA |
|
Alternative Names |
lipid-siRNA or liposome-encapsulated siRNA |
|
Adjuvant VO ID |
VO_0005645
|
|
Description |
L-siRNA refers to small interfering RNA (siRNA) that is encapsulated in lipid nanoparticles (coatsomes) designed for efficient delivery into cells to silence specific target genes, such as SOCS1. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Lipid nanoparticle-enclosed siRNA (L-siRNA) transported into primary cells without any toxic side effects and protected from early degradation |
|
Structure |
L-siRNA consists of a double-stranded RNA molecule designed to target specific mRNA for degradation, encapsulated in lipid nanoparticles that facilitate cellular uptake. |
|
Preparation |
L-siRNA is prepared by packaging siRNA into lipid nanoparticles, which involves mixing the siRNA with lipid components that form vesicles capable of encapsulating the RNA. |
|
Dosage |
In the study, L-siRNA was used at concentrations of 50 ul/ml and 100 ul/ml. |
|
Function |
STAT3 induces expression of suppressor of cytokine signaling (SOCS) 1 that terminates the inflammatory response. In the approach, TLR4-adjuvant monophosphoryl lipid A (MPLA)-stimulated monocyte-activation is reinforced and sustained by silencing SOCS1 via lipid nanoparticle-enclosed siRNA (L-siRNA). |
|
Safety |
The article suggests that L-siRNA has a low toxicity profile and is designed to minimize adverse effects while effectively delivering siRNA to target cells. |
| References |
Hildebrand et al., 2019: Hildebrand D, Metz-Zumaran C, Jaschkowitz G, Heeg K. Silencing SOCS1 via Liposome-Packed siRNA Sustains TLR4-Ligand Adjuvant. Frontiers in immunology. 2019; 10; 1279. [PubMed: 31214204].
|
